FDA Releases Guidance on Tobacco Product Warning Labels and Ads

Regulations by 2FIRSTS.ai
Sep.13.2024
FDA Releases Guidance on Tobacco Product Warning Labels and Ads
FDA issues new guidance on tobacco warning labels, following court challenges, with plans for enforcement in 2025.

On September 12th, the U.S. Food and Drug Administration (FDA) website announced that they are providing guidance on the final rule regarding "Tobacco Products; Required Warnings for Cigarette Packages and Advertisements." The rule aims to promote greater public understanding of the negative health effects of smoking by adding new health warnings to cigarette packaging and advertisements.


The final rule was published in March 2020 and faced a challenge in the Eastern District Court of Texas. In December 2022, the district court overturned the rule. However, the government appealed this decision, and in May 2024, the United States Fifth Circuit Court of Appeals overturned the district court's ruling, reinstating the final rule, which is now officially in effect. The plaintiffs are now waiting for review by the Supreme Court.


In the newly released guidance document, the FDA plans to exercise enforcement discretion for 15 months or until December 12, 2025, generally not enforcing the requirements of final rules. For products manufactured before December 12, 2025, the FDA will also provide an additional 30-day grace period, or until January 12, 2026. The FDA has chosen a 15-month orderly transition period, consistent with the initially envisioned 15-month compliance period of the Family Smoking Prevention and Tobacco Control Act, but impacted by litigation proceedings.


The final rule also requires the industry to submit plans and obtain FDA approval to ensure that warning labels on cigarette packaging are displayed and distributed randomly and evenly, while rotating warning labels on cigarette advertisements quarterly. Therefore, entities with cigarette health warning plans that have not yet been approved are advised to submit such plans as soon as possible, but must do so within five months or by February 10, 2025. Entities that had previously submitted cigarette plans to the FDA do not need to resubmit their plans unless they wish to make changes.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Annual Meeting Flags “New Growth Drivers” for 2026: Cigarette Innovation, Domestic Cigars, Overseas Business and Multi-Purpose Use
China Tobacco Annual Meeting Flags “New Growth Drivers” for 2026: Cigarette Innovation, Domestic Cigars, Overseas Business and Multi-Purpose Use
China’s tobacco authorities used their annual industry meeting in Beijing to outline new growth drivers for 2026, highlighting cigarette innovation, domestic cigars, overseas business expansion and multi-purpose tobacco applications.
Special Report
Jan.20
Alabama House Health Committee advances SB9 to restrict vaping in public spaces under Clean Indoor Air Act
Alabama House Health Committee advances SB9 to restrict vaping in public spaces under Clean Indoor Air Act
The Alabama House Health Committee passed Senate Bill 9 on Wednesday to restrict vaping in public areas under the state’s Clean Indoor Air Act. Introduced by Sen. Gerald Allen, SB9 would add vapes—defined as “electronic nicotine delivery systems”—to the forms of “smoking” currently prohibited in enclosed public places.
Feb.13 by 2FIRSTS.ai
Nicaragua’s Health Ministry reaffirms Resolution No. 334-2021, maintaining a total ban on vaping and e-cigarette sales
Nicaragua’s Health Ministry reaffirms Resolution No. 334-2021, maintaining a total ban on vaping and e-cigarette sales
Nicaragua’s Ministry of Health (MINSA) issued an official statement on January 2, 2026 reaffirming the validity of Ministerial Resolution No. 334-2021, which absolutely bans the use and commercialization of electronic nicotine delivery systems known as “vapeadores” or e-cigarettes.
Jan.04 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
Haypp Reports 15% Q4 Sales Growth as Nicotine Pouch Volumes Rise
Haypp Reports 15% Q4 Sales Growth as Nicotine Pouch Volumes Rise
Haypp Group announced that net sales for October–December 2025 rose 15% year-on-year to SEK 1,052.2 million, or 19% in constant currency terms. The company recorded 28% volume growth in the nicotine pouch category during the quarter. The number of orders increased to 1.34 million, and active consumers rose to 630,000, marking the highest level in the company’s history. CEO Gavin O’Dowd said the company’s accelerating topline performance in the US and UK positions it for a strong 2026.
Market
Feb.22
BAT Malaysia names Mohd Nizom Sairi as board chairman effective January 1, 2026
BAT Malaysia names Mohd Nizom Sairi as board chairman effective January 1, 2026
BAT Malaysia announced that its independent non-executive director Datuk Seri Dr Mohd Nizom Sairi has been re-designated as board chairman effective January 1, 2026.
Jan.04 by 2FIRSTS.ai